Thanks Tony,
Interesting discussion around neuro-developmental disorders. Roche is actively involved into research in ASD's. Virani specifically mentioned Fragile X and Rett Syndrome as areas of interest due to incredibly high unmet need and the belief that 'the science is evolving'.
One cannot be categorical of course but the reference surely includes the evolving science around IGF-1. The nomination of Fragile X and Retts is incredibly coincidental given the progress by Neuren in this space.
Regards,
Wayne
global head neuroscience partnering at roche, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
0.550(3.71%) |
Mkt cap ! $1.915B | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.50 | $14.91 | $9.641M | 631.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $15.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.39 | 1224 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |